- Home
- OPRX vs CRBP Comparison
OPRX vs CRBP Comparison
Compare OPRX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPRX
- CRBP
- Stock Information
- Founded
- OPRX 2006
- CRBP 2009
- Country
- OPRX United States
- CRBP United States
- Employees
- OPRX N/A
- CRBP N/A
- Industry
- OPRX Business Services
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- OPRX Consumer Discretionary
- CRBP Health Care
- Exchange
- OPRX Nasdaq
- CRBP Nasdaq
- Market Cap
- OPRX 137.6M
- CRBP 73.4M
- IPO Year
- OPRX N/A
- CRBP N/A
- Fundamental
- Price
- OPRX $8.09
- CRBP $5.52
- Analyst Decision
- OPRX Buy
- CRBP Strong Buy
- Analyst Count
- OPRX 8
- CRBP 10
- Target Price
- OPRX $9.06
- CRBP $60.89
- AVG Volume (30 Days)
- OPRX 515.1K
- CRBP 215.6K
- Earning Date
- OPRX 05-13-2025
- CRBP 05-06-2025
- Dividend Yield
- OPRX N/A
- CRBP N/A
- EPS Growth
- OPRX N/A
- CRBP N/A
- EPS
- OPRX N/A
- CRBP N/A
- Revenue
- OPRX $92,127,000.00
- CRBP N/A
- Revenue This Year
- OPRX $12.12
- CRBP N/A
- Revenue Next Year
- OPRX $10.87
- CRBP $150.00
- P/E Ratio
- OPRX N/A
- CRBP N/A
- Revenue Growth
- OPRX 28.81
- CRBP N/A
- 52 Week Low
- OPRX $3.78
- CRBP $4.64
- 52 Week High
- OPRX $14.13
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- OPRX 50.73
- CRBP 38.99
- Support Level
- OPRX $6.80
- CRBP $4.64
- Resistance Level
- OPRX $8.32
- CRBP $5.99
- Average True Range (ATR)
- OPRX 0.77
- CRBP 0.43
- MACD
- OPRX -0.19
- CRBP 0.12
- Stochastic Oscillator
- OPRX 29.11
- CRBP 52.29
About OPRX OptimizeRx Corporation
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.